Milestone Scientific (MLSS) AI Stock Analysis

• Market Cap: $32.60M
• Dividend Yield: N/A
• Average Volume (3M): 172.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.54
• Revenue Growth: 7.84%
• EPS Growth: -43.00%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.02
• Shares Outstanding: 78,559,150
• 10 Day Avg. Volume: 233,274
• 30 Day Avg. Volume: 172,658
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.60
• Enterprise Value/Revenue: 5.73
• Enterprise Value/Gross Profit: 7.87
• Enterprise Value/Ebitda: -7.59
• 1Y Price Target: $1.63
• Price Target Upside: 279.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 41 Neutral
• Price Target: $0.50 ▲(16.28% Upside)

Milestone Scientific's overall stock score is primarily impacted by its challenging financial performance, characterized by ongoing losses and cash flow issues. Technical analysis indicates bearish momentum, with the stock trading below key moving averages and oversold indicators. The negative P/E ratio and lack of dividend yield further contribute to a low valuation score.

Positive Factors

Leadership Change

The appointment of a new CEO and the strategic initiatives he has introduced could lead to improved operational efficiency and market expansion, potentially enhancing the company's competitive position and financial performance over the long term.

Product Innovation

The relaunch of CompuFlo technology, with a focus on healthcare settings, suggests a strategic expansion into new markets, which could drive future revenue growth and strengthen Milestone's market position.

Operational Efficiency

Reducing operating expenses by 20% indicates a focus on improving cost efficiency, which can enhance profitability and provide a stronger financial foundation for sustained growth.

Negative Factors

Stockholder Equity

Non-compliance with NYSE equity requirements poses a risk to the company's listing status, which could impact investor confidence and access to capital markets, potentially affecting long-term growth prospects.

Financial Performance

The persistent negative net profit margin and ongoing losses highlight operational inefficiencies and financial challenges, which may hinder the company's ability to achieve sustainable profitability and growth.

Cash Flow Issues

Negative cash flows suggest difficulties in generating sufficient cash from operations, which can limit the company's ability to invest in growth initiatives and maintain financial stability over the long term.

Milestone Scientific Business Overview & Revenue Model

Company Description

Milestone Scientific Inc. (MLSS) is a biotechnology company specializing in the development of innovative drug delivery technology and solutions. The company operates primarily in the medical device sector, focusing on the dental and obstetric markets. Milestone's core products include the CompuFlo® instrument, which utilizes patented technology for precise and controlled delivery of anesthetic agents, enhancing patient comfort and safety during procedures.

How the Company Makes Money

Milestone Scientific generates revenue primarily through the sale of its medical devices and related consumables. The main revenue streams include direct sales of the CompuFlo® system to dental and medical practitioners, as well as recurring revenue from the sale of disposable components that accompany the device. Additionally, the company may benefit from partnerships with healthcare organizations and distributors that expand market reach and enhance sales opportunities. Licensing agreements and collaborations with research institutions further contribute to its earnings by allowing Milestone to leverage its technology and expertise in broader applications.

Milestone Scientific Financial Statement Overview

Summary

Milestone Scientific demonstrates strong gross profit margins and low leverage, but persistent net losses and negative cash flows highlight ongoing financial challenges. The company needs to enhance revenue growth and improve operational efficiencies to achieve profitability and strengthen its financial position.

Income Statement

Milestone Scientific shows a declining revenue trend with a steep drop of 34.52% from 2023 to 2024. Gross profit margins are strong at 100% for 2024, indicating effective cost control. However, the net profit margin remains negative due to consistent operating losses, despite slight improvements in EBIT and EBITDA margins.

Balance Sheet

The company's debt-to-equity ratio is low at 0.06, indicating minimal leverage, a positive sign of financial stability. However, the return on equity remains negative, reflecting ongoing losses. Equity ratio remains robust, showcasing a solid foundation of equity in its asset base.

Cash Flow

Operating cash flow has improved from a severe deficit but remains negative, showing challenges in generating cash from core operations. Free cash flow is also negative, indicating a strain on liquidity. Positive investing cash flow suggests asset divestment or reduced investment, which could impact future growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.08M	8.63M	9.83M	8.81M	10.30M	5.44M
Gross Profit	6.61M	6.43M	6.79M	4.90M	6.31M	3.62M
EBITDA	-6.86M	-6.72M	-6.96M	-8.68M	-7.30M	-7.36M
Net Income	-6.97M	-4.71M	-6.93M	-8.71M	-7.12M	-7.49M
Balance Sheet
Total Assets	8.05M	9.80M	11.37M	13.70M	19.81M	19.57M
Cash, Cash Equivalents and Short-Term Investments	1.27M	3.26M	5.95M	8.72M	14.76M	14.22M
Total Debt	1.09M	349.05K	395.98K	497.04K	586.59K	942.60K
Total Liabilities	4.71M	3.96M	3.36M	3.70M	3.59M	3.46M
Stockholders Equity	3.34M	5.83M	8.01M	10.23M	16.37M	16.20M
Cash Flow
Free Cash Flow	-5.26M	-2.93M	-5.33M	-6.04M	-4.03M	-7.01M
Operating Cash Flow	-5.26M	-2.92M	-5.33M	-6.03M	-4.02M	-6.98M
Investing Cash Flow	-2.98M	2.97M	-2.97M	-8.53K	-15.19K	-21.44K
Financing Cash Flow	789.19K	233.77K	2.56M	-8.54K	4.57M	19.71M

Milestone Scientific Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLSS, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.52, and below the 200-day MA of 0.81, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 40.98 is Neutral, neither overbought nor oversold. The STOCH value of 43.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLSS.

Milestone Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEPH	―	$55.44M	41.87	15.14%	―	21.16%	―
RVP	―	$26.90M	-3.00	-10.80%	―	-0.24%	50.45%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FEMY	―	$27.07M	―	-329.45%	―	98.61%	-1.98%
NXGL	―	$27.70M	―	-66.08%	―	133.00%	29.69%
POCI	―	$33.17M	-5.06	-51.78%	―	-0.07%	-74.60%
MLSS	―	$32.60M	-4.78	-123.50%	―	7.84%	-43.00%

Milestone Scientific Corporate Events

Milestone Scientific Faces NYSE Non-Compliance Notice

On October 8, 2025, Milestone Scientific Inc. received a notice from NYSE American LLC indicating non-compliance with certain listing standards. The company must submit a compliance plan by November 7, 2025, to maintain its listing, with potential delisting if standards are not met by April 8, 2027.

The most recent analyst rating on (MLSS) stock is a Buy with a $1.25 price target. To see the full list of analyst forecasts on Milestone Scientific stock, see the MLSS Stock Forecast page.

Milestone Scientific Reports Increased Sales but Faces Losses

Milestone Scientific Inc., a Delaware-based company, specializes in developing computer-controlled anesthetic delivery devices for dental and medical applications, with a focus on innovative technology in the healthcare sector. In its latest earnings report for the quarter ended June 30, 2025, Milestone Scientific Inc. highlighted a net loss of $1.48 million, compared to a net income of $223,638 in the same quarter of the previous year. The company reported product sales of $2.32 million, a notable increase from $1.85 million in the same period last year, driven by a rise in dental segment sales. Despite an increase in gross profit to $1.62 million, the company faced higher operating expenses, which contributed to the overall loss. Milestone Scientific’s financial performance was impacted by increased selling, general, and administrative expenses, as well as research and development costs. The company continues to face challenges related to its cash flow and liquidity, with cash and cash equivalents decreasing to $1.27 million from $3.26 million at the end of 2024. Looking ahead, Milestone Scientific’s management remains focused on securing additional funding to support its operations and aims to enhance revenue generation from its dental and medical device segments, while also working to reduce operating expenses.

Milestone Scientific Appoints Eric C. Hines as CEO

On August 1, 2025, Milestone Scientific Inc. announced the appointment of Eric C. Hines as the new Chief Executive Officer, effective immediately. Hines, with over 25 years of leadership experience in scaling sales-driven enterprise software companies, is expected to drive the company’s next phase of commercial execution. His appointment comes at a pivotal moment as Milestone Scientific aims to expand its presence in the medical and dental markets, leveraging recent achievements in reimbursement and the potential of its CompuFlo® technology. The company believes Hines’s expertise will help accelerate the adoption of their technology and guide them in pursuing new clinical indications and global opportunities.

The most recent analyst rating on (MLSS) stock is a Buy with a $1.25 price target. To see the full list of analyst forecasts on Milestone Scientific stock, see the MLSS Stock Forecast page.